Balaji Amines Ltd
Balaji Amines Ltd Q3 FY24 Results & Presentation Highlights: Revenue ₹392 Cr, PAT ₹56 Cr
Q3 FY24 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaji Amines Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY24 consolidated revenue from operations: ₹392 crore, down 33% YoY from ₹588 crore in Q3FY23 (Page 5, 7). Q3FY24 Consolidated EBITDA: ₹83 crore (up from ₹61 crore in Q2FY24) - Q3FY24 Consolidated EBITDA Margin: 21% (up from 16% in Q2FY24; down YoY from 22% in Q3FY23) - Q3FY24 Consolidated PAT: ₹56 cro
From Balaji Amines Ltd's Q3 FY24 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3FY24 consolidated revenue from operations: ₹392 crore, down 33% YoY from ₹588 crore in Q3FY23 (Page 5, 7).
- Q3FY24 volumes: total 26,903 MT vs 27,613 MT in Q2FY24; no explicit YoY volume figures given (Page 7).
- Q3FY24 segmented volumes: Amines 7,703 MT, Amines Derivatives 9,280 MT, Specialty Chemicals 9,920 MT (Page 7).
- Q3FY24 standalone revenue: ₹314 crore, down 24% YoY from ₹416 crore in Q3FY23 (Page 5).
- 9MFY24 consolidated revenue: ₹1,248 crore, down 34% YoY from ₹1,894 crore in 9MFY23 (Page 6).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Unit 4 Greenfield Project (90-acre in MIDC Chincholi, Solapur):
- Phase 1 completed: Ethylamines plant (operational May 2021), DMC/PC and PG plants (operational Sep 2022).
- Phase 2 & 3 Capex: Rs. 300-350 crore over FY24 and FY25, mostly internal accruals.
- Phase 2 Expansion:
- n-Butylamine plant (15,000 TPA), targeted commissioning Q4 FY24.
- Methylamine plant (40,000 TPA capacity), commissioning Q2 FY25; company is market leader with 48,000 TPA installed capacity.
- Phase 3 Expansion:
- Dimethyl Ether (DME) plant (100,000 TPA), commissioning H1 FY25.
- Proposed additions: N-Methylmorpholine, Pharmapure Povidone, NBPT.
- Other details:
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Balaji Amines Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹395 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaji Amines Ltd's management said in earlier quarters
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q4 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Himadri Speciality Chemical Ltd (Q3 FY24)
1,052.51 Cr, up 1.46% YoY from Rs. Key investor presentation takeaways from Himadri Speciality Chemical Ltd's Q3 FY24 investor presentation — and how it ranks a
- Gujarat Alkalies & Chemicals Ltd (Q3 FY24)
3,702.77 crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY24 investor presentation — and how it ranks agai
- Vidhi Specialty Food Ingredients Ltd (Q3 FY24)
Year-on-Year (Y-o-Y) change: -27.1% (Q3 FY24 vs Q3 FY23) . Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY24 investor pres
- Chemcon Speciality Chemicals Ltd (Q3 FY24)
53.0 Cr, down 30.7% YoY from Rs. Key investor presentation takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY24 investor presentation — and how it ranks ag
Frequently Asked Questions
What were Balaji Amines Ltd Q3 FY24 results?
Q3FY24 consolidated revenue from operations: ₹392 crore, down 33% YoY from ₹588 crore in Q3FY23 (Page 5, 7). Q3FY24 Consolidated EBITDA: ₹83 crore (up from ₹61 crore in Q2FY24) - Q3FY24 Consolidated EBITDA Margin: 21% (up from 16% in Q2FY24; down YoY from 22% in Q3FY23) - Q3FY24 Consolidated PAT: ₹56 cro
What is Balaji Amines Ltd share price analysis?
Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaji Amines Ltd planning capital expenditure?
Unit 4 Greenfield Project (90-acre in MIDC Chincholi, Solapur): - Phase 1 completed: Ethylamines plant (operational May 2021), DMC/PC and PG plants (operational Sep 2022). - Phase 2 & 3 Capex: Rs.
Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.